NOD mouse model for Sjogren's syndrome: lack of longitudinal stability

被引:28
作者
Lodde, B. M.
Mineshiba, F.
Kok, M. R.
Wang, J.
Zheng, C.
Schmidt, M.
Cotrim, A. P.
Kriete, M.
Tak, P. P.
Baum, B. J.
机构
[1] NIDCR, GTTB, NIH, DHHS, Bethesda, MD 20892 USA
[2] Univ Amsterdam, Acad Med Ctr, NL-1105 AZ Amsterdam, Netherlands
[3] NIDCR, Vet Resoures Core, NIH, DHHS, Bethesda, MD USA
关键词
Sjogren's syndrome; NOD mouse model; phenotype; salivary gland; autoimmune disease;
D O I
10.1111/j.1601-0825.2006.01241.x
中图分类号
R78 [口腔科学];
学科分类号
1003 ;
摘要
OBJECTIVES: The non-obese diabetic (NOD) mouse is not only a widely used model for diabetes mellitus type I, but also for the chronic autoimmune disease Sjogren's syndrome (SS), mainly affecting salivary and lacrimal glands. We studied the efficacy of local recombinant serotype 2 adeno-associated viral (rAAV2) vector transfer of immunomodulatory transgenes to alter the SS-like disease in NOD mice. Data collected over a 2-year period indicated a changing SS phenotype in these mice and this phenomenon was investigated. METHODS: 10(10) particles rAAV2LacZ/gland were delivered to both submandibular glands (SMGs) of NOD/LtJ mice at 8 weeks (before sialadenitis onset) of age. Salivary flow rates were determined at 8 weeks and time of killing. Blood glucose levels and body weights were measured weekly. After killing, saliva and SMGs were harvested. Analyses of salivary output, inflammatory infiltrates (focus score), SMG cytokine profile, body weight, and diabetes mellitus status were performed. Data from six different experimental studies over 2 years were analyzed and compared. RESULTS: Salivary flow rate, focus score, and SMG cytokines interleukin (IL)-2, IL-4, IL-6, IL-10, IL-12(p70), tumor necrosis factor-alpha and IFN gamma showed changes over time. There were no differences for body weight, diabetes mellitus prevalence, or blood glucose level of non-diabetic mice. CONCLUSION: This retrospective report is the first to describe longitudinal variability in the NOD mouse as a model for SS. We advise other investigators to continuously monitor the SS phenotype parameters and include appropriate controls when studying this disease in NOD mice.
引用
收藏
页码:566 / 572
页数:7
相关论文
共 35 条
[1]   GROUP-SIZE, CAGE SHELF LEVEL, AND EMOTIONALITY IN NONOBESE DIABETIC MICE - IMPACT ON ONSET AND INCIDENCE OF IDDM [J].
ADER, DN ;
JOHNSON, SB ;
HUANG, SW ;
RILEY, WJ .
PSYCHOSOMATIC MEDICINE, 1991, 53 (03) :313-321
[2]   The NOD mouse: A model of immune dysregulation [J].
Anderson, MS ;
Bluestone, JA .
ANNUAL REVIEW OF IMMUNOLOGY, 2005, 23 :447-485
[3]   HIGH AND LOW DIABETES INCIDENCE NONOBESE DIABETIC (NOD) MICE - ORIGINS AND CHARACTERIZATION [J].
BAXTER, AG ;
KOULMANDA, M ;
MANDEL, TE .
AUTOIMMUNITY, 1991, 9 (01) :61-67
[4]   Immunopathogenesis of Sjogren's syndrome [J].
Borchers, AT ;
Naguwa, SM ;
Keen, CL ;
Gershwin, ME .
CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY, 2003, 25 (01) :89-104
[5]   PREVENTION OF DIABETES IN THE NOD MOUSE - IMPLICATIONS FOR THERAPEUTIC INTERVENTION IN HUMAN-DISEASE [J].
BOWMAN, MA ;
LEITER, EH ;
ATKINSON, MA .
IMMUNOLOGY TODAY, 1994, 15 (03) :115-120
[6]   Adenoassociated virus-mediated transfer of a functional water channel into salivary epithelial cells in vitro and in vivo [J].
Braddon, VR ;
Chiorini, JA ;
Wang, SL ;
Kotin, RM ;
Baum, BJ .
HUMAN GENE THERAPY, 1998, 9 (18) :2777-2785
[7]   Two NOD Idd-associated intervals contribute synergistically to the development of autoimmune exocrinopathy (Sjogren's syndrome) on a healthy murine background [J].
Cha, S ;
Nagashima, H ;
Brown, VB ;
Peck, AB ;
Humphreys-Beher, MG .
ARTHRITIS AND RHEUMATISM, 2002, 46 (05) :1390-1398
[8]   Progress in understanding autolmmune exocrinopathy using then on-obese diabetic mouse: An update [J].
Cha, S ;
Peck, AB ;
Humphreys-Beher, MG .
CRITICAL REVIEWS IN ORAL BIOLOGY & MEDICINE, 2002, 13 (01) :5-16
[9]   High-efficiency transfer of the T cell co-stimulatory molecule B7-2 to lymphoid cells using high-titer recombinant adeno-associated virus vectors [J].
Chiorini, JA ;
Wendtner, CM ;
Urcelay, E ;
Safer, B ;
Hallek, M ;
Kotin, RM .
HUMAN GENE THERAPY, 1995, 6 (12) :1531-1541
[10]   Recombinant adeno-associated virus vectors for gene therapy [J].
Conlon, TJ ;
Flotte, TR .
EXPERT OPINION ON BIOLOGICAL THERAPY, 2004, 4 (07) :1093-1101